Bicycle therapeutics to present five posters highlighting preclinical data from its bicycle tumor-targeted immune cell agonist® (bicycle tica®) programs at the sitc 37th annual meeting

Cambridge, england, & boston--(business wire)--bicycle therapeutics plc (nasdaq:bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that preclinical data for bt7480, a novel bicycle tumor-targeted immune cell agonist (bicycle tica), and bt7455, an epha2/cd137 bicycle tica, will be presented in five poster presentations at the society for immunotherapy of cancer's (sitc) 37th ann
BCYC Ratings Summary
BCYC Quant Ranking